Dermatology

ACR: UHC's New Co-pay Policy Is "Disastrous" for Patients

October 29, 2020

Tony Hagen

Article

The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD

Article

European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Celltrion Healthcare Advances Trials for Omalizumab Biosimilar

October 9, 2020

Tony Hagen

Article

The product would target the lucrative, billion-dollar worldwide market for Xolair.

Stakeholders Joust Over Biosimilar Availability at PCOC20

September 25, 2020

Tony Hagen

Article

A diverse panel from practice, payer, and wholesale perspectives convened at The American Journal of Managed Care®'s Patient-Centered Oncology Care® 2020 virtual conference to hash out one of the hottest issues in biosimilar availability right now.

Report: PBM "Reforms" Leave Biosimilars Out in the Cold

September 2, 2020

Tony Hagen

Article

It’s same old, same old when it comes to pharmacy benefit manager (PBM) contracts despite much touted reforms, authors of a review contend.

Investigators Eye Gaps in Biosimilar Assessment Reports

August 31, 2020

Deana Ferreri, PhD

Article

Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.

Winegarden: Biosimilars Market Lacks Oomph

August 17, 2020

Tony Hagen

Article

A Pacific Research Institute economist says that by his scorecard, biosimilars are not supercharging the market the way they ought to be doing .

Pfizer Expert Urges Employers to Get Proactive on Biosimilars

August 13, 2020

Tony Hagen

Article

Defining biosimilar use in the United States as "sluggish," Juliana Reed, MS, said employers have to get involved.

Revance Moves Forward With 2 Botox Competitors

August 7, 2020

Skylar Jeremias

Article

With a sizable milestone payment from its partner Mylan, Revance has stepped up efforts to launch contenders in the Botox space.

Vizient Looks to Biosimilars To Temper COVID-19 Price Inflation

July 31, 2020

Skylar Jeremias

Article

Vizient predicts that drug price inflation, partly due to the coronavirus disease 2019 (COVID-19), will be 3.29% in 2021 and is banking on biosimilars to help contain the rising cost of medication, it said in a comprehensive review for its member health companies.

x